The union for managers and professionals in public service
Home  >  News and media  >  News  >  FDA calls for substantial reform of NCA pay structure
Wednesday 15 May 2024

FDA calls for substantial reform of NCA pay structure

Willy Barton/Shutterstock.com

Every year the FDA gives evidence to the National Crime Agency Renumeration Review Body (NCARRB), which makes independent recommendations to the government on the pay and allowances of National Crime Agency (NCA) officers designated with operational powers.

In its evidence to the NCARRB for 2024 the FDA argues for urgent reform of the NCA pay structure. An FDA survey found that members thought it was extremely or very important that the pay system rewarded increased skills, knowledge and experience. However, none of the respondents could currently see a clear link between their pay and their performance in their experience of the current pay arrangements. 

Commenting on the FDA’s evidence, FDA National Officer for the NCA Wynne Parry said:

 “Pay in the Agency remains significantly behind Police pay and increasingly is becoming less competitive for senior staff in the wider civil service. The FDA recognises the government imposed constraints that have dictated the NCA approach to pay, our members cannot afford to see their pay fall further behind. It is crucial that the momentum for pay reform is supported by the Treasury with sufficient funding to secure the long-term future of the agency.”

Read the FDA's full evidence

21st Jun 2024
This Pride Month, a delegation of FDA members will attend the TUC LGBT+ Conference in London. Our lead delegate and Executive Committee member Simon Percelay looks ahead to the conference and reflects on the state of play of LGBT+ equality in the civil service.
13th Jun 2024
If you are from a disadvantaged background, it is clear that becoming a member of a trade union, and particularly the FDA, improves your chances of getting in and getting on.
Find us
FDA, Centenary House, 93-95 Borough High Street, London, SE1 1NL                      
Copyright © 2024 FDA